TITLE

Align Acquisition Pads Cyclacel's Resource Base

AUTHOR(S)
Young, Donna
PUB. DATE
October 2007
SOURCE
BioWorld Today;10/9/2007, Vol. 18 Issue 196, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
This article reports on the acquisition of Align Pharmaceuticals LLC by Cyclacel Pharmaceuticals Inc. in a deal worth up to $3.8 million in cash. Aside from the cash, the deal also involves stock paid to Align Holding LLC. Cyclacel Pharmaceuticals is involved in the development of products for hematological and solid tumor cancers, prescription drugs used to manage the effects of radiation and chemotherapy in cancer patients.
ACCESSION #
26998028

 

Related Articles

  • Company News.  // Pharmaceutical Discovery;Oct2005, Vol. 5 Issue 8, p10 

    Reports developments related to pharmaceutical discovery in the U.S. Accounts on the two joint marketing agreements between PerkinElmer Inc. and Invitrogen Corp.; Details on the merger agreement of Pharmagene PK with Asterand Inc.; Contract signed between GangaGene Life Sciences Inc. and Elanco...

  • Past is Prologue. Hoffman, Michelle // Drug Discovery & Development;Aug2006, Vol. 9 Issue 8, p4 

    The author reflects on the science, art, and business of drug discovery and development in the U.S. She provides insights into the merger between biotechnology firm Genentech and Roche, a pharmaceutical company. The author also discusses the access of pharmaceutical firms to novel compounds and...

  • Still Breathing. Abejo, Jerry // Mergers & Acquisitions: The Dealermaker's Journal;Jun2008, Vol. 43 Issue 6, p64 

    The article reports that field of Life science merger and acquisition (M&A) has a belief that pharmaceutical dealings were immune to the deal market's ups and downs. It is averred that dealmakers are pressured to think long-term due to the patient and unsure nature of drug development. It is...

  • Is more consolidation in store for pharma? Iskowitz, Marc // Medical Marketing & Media;Apr2006, Vol. 41 Issue 4, p34 

    The article examines reasons for the lack of big acquisitions in the United States. One reason is that the marketplace rewards top-line growth better than restructuring organizations or people. Another rationale is that companies have been preoccupied with in-licensing that vows new drugs and...

  • Acquisition of 100% shareholding of formulation dossier registration holding companies in Australia and New Zealand.  // Chemical Business;Oct2007, Vol. 21 Issue 10, p63 

    The article reports on the acquisition by the Indian Pharmaceutical Combine Association (IPCA) Laboratories Ltd. of 100% shareholding of a small formulation product dossier registration-cum-distribution company in New Zealand and Australia, in October 2007. IPCA is involved in the production and...

  • CYCLACEL REPORTS PROGRESS WITH 2ND GENERATION CDK INHIBITOR.  // Worldwide Biotech;Jul2003, Vol. 15 Issue 7, p4 

    Focuses on the cyclin dependent kinase inhibitors for the genes-to-drugs CYC400 rational drug design program of the biopharmaceutical firm Cyclacel Ltd. in Great Britain.

  • Cyclacel to speed up Altana drug development.  // PharmaWatch: Cancer;May 2005, Vol. 4 Issue 5, p15 

    Reports that Cyclacel Group PLC and Altana Pharma AG have signed a research collaboration agreement to identify molecular agents of experimental cancer drugs. Terms of the agreement; Comments of the chief scientist of Cyclacel's Polgen division, David Glover regarding on the discovery of...

  • Threats.  // PharmaWatch: CNS;May2012, Vol. 11 Issue 5, p22 

    The article presents an analysis of threats of global provider of generic pharmaceuticals Teva Pharmaceutical Industries Ltd. It notes that opportunities of Teva Pharmaceutical Industries Ltd. for further growth is hampered by the loss of additional targets of merger and acquisition (M&A) deal....

  • Lilly Gets Technology Boost from SGX.  // Bioworld Week;7/14/2008, Vol. 16 Issue 28, p4 

    The article reports on the merger of Eli Lilly & Co. and SGX Pharmaceuticals Inc. in the U.S. As stipulated in the deal, Eli Lilly will acquire all shares of common stock for access to SGX's preclinical oncology programs and drug discovery platforms. These platforms inlcude FAST, a protein...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics